Gemcitabine suppresses myeloid-derived suppressor cells (MDSCs), upregulates expression of immune accessory molecules and adhesion molecules (e.g., CD80, CD86, CD40, ICAM-1), and increases tumor-specific T cell responses in a mouse model of oral cancer [59]. This evidence concerns the gene CD40 and neoplasm.